Related Experiment Video

Updated: Apr 19, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

[Advance in microRNAs and EGFR-TKIs secondary resistance research in non-small cell lung cancer]

Xiaoyang Duan1, Jian Shi2

  • 1Graduate Student of Hebei Medical University, Shijiazhuang 050000, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|December 26, 2014
PubMed

Insights

MicroRNAs (miRNAs) play a role in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in non-small cell lung cancer (NSCLC). Understanding miRNA involvement is key to overcoming treatment resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) treatment increasingly utilizes epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).
  • Acquired resistance to EGFR-TKIs is a major challenge, limiting treatment efficacy and leading to disease progression.
  • MicroRNAs (miRNAs), small non-coding RNAs, regulate gene expression and are implicated in various cellular processes, including drug resistance.

Purpose of the Study:

  • To review recent advancements in understanding the role of miRNAs in acquired resistance to EGFR-TKIs in NSCLC.
  • To highlight how miRNAs influence the sensitivity of cancer cells to targeted therapies.

Main Methods:

  • Literature review of studies investigating miRNAs and EGFR-TKI resistance in NSCLC.
  • Analysis of current research on the mechanisms by which miRNAs affect treatment sensitivity.

Main Results:

  • Emerging evidence indicates that miRNAs are significantly involved in the development of secondary resistance to EGFR-TKIs.
  • Specific miRNAs can either promote or inhibit resistance, impacting tumor cell response to therapy.

Conclusions:

  • MiRNAs represent a critical factor in EGFR-TKI resistance in NSCLC.
  • Further research into miRNA-mediated resistance mechanisms is essential for developing strategies to improve targeted therapy outcomes.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K